Antibe Therapeutics Inc.
ATE
Classifica tra le azioni
#31906
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Prezzo delle azioni
$0.21483059
Ultima sincronizzazione: 2024-05-07
Capitalizzazione di mercato
$11.13M
Variazione (1 giorno)
0.34%
Variazione (1 anno)
-0.36%
Paese
CA
Scambia Antibe Therapeutics Inc. (ATE)
Categoria
Healthcare
Storico del rendimento da dividendi per Antibe Therapeutics Inc. (ATE)
Il rendimento da dividendi (TTM) di Antibe Therapeutics Inc. (simbolo azionario: ATE) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Antibe Therapeutics Inc. (ATE) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
| Anno | Rendimento da dividendi | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
| Azienda | Rendimento da dividendi | Il paese |
|---|---|---|
| 2.45% |
US
|
|
| 3.69% |
IE
|
|
| 1.25% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
DE
|
